Papathanassiou M., Tamposis I., Exarchou-Kouveli K.K., Kontou P.I., de Paz A.T., Mitrakas L., Samara M., Bagos P.G., Tzortzis V., Vlachostergios P.J. (2022)
Introduction: The use of immune checkpoint inhibitors (ICIs) as a front-line treatment for metastatic renal cell carcinoma (RCC) has significantly improved patient’ outcome. However, little is known about the efficacy or ...